Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) | RFA DK 19 003

Opportunity Information: Apply for RFA DK 19 003

The Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) funding opportunity (RFA-DK-19-003) is an NIH program administered by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support institution-based core centers focused on cystic fibrosis (CF). The main purpose is to strengthen and accelerate both basic and clinical CF research by funding shared infrastructure rather than standalone research projects. These centers are meant to help investigators develop, refine, and test new therapies for CF, and to make it easier for scientists and clinicians to collaborate across departments and, where appropriate, across institutions that already have a strong CF research base.

A key feature of the program is the required structure of the center, which is built around three major components. First, the Research Cores provide shared services, technologies, resources, and expertise that multiple investigators can use, reducing duplication and raising overall research quality and efficiency. Second, the program includes a Pilot and Feasibility (P and F) program, designed to seed new ideas, help investigators generate preliminary data, and bring new researchers into CF-related work, with the goal of enabling subsequent, larger independent grants and more mature translational efforts. Third, applicants must propose an Administrative Core that manages governance, tracking, communications, and evaluation, and it must include an enrichment program to build community and momentum around CF research (for example, seminars, visiting speakers, workshops, training or mentoring activities, and other efforts that stimulate collaboration and scientific exchange).

The opportunity is positioned as a "core center" mechanism (P30), meaning it is intended to provide an institutional backbone that supports multiple ongoing CF research projects rather than funding one narrow research aim. While clinical trials are optional under this announcement, the overall mission is explicitly translational: building the shared capacity needed to move discoveries toward practical interventions, including therapeutic development and testing. NIDDK noted it already supported seven CF Research and Translation Centers at the time of the announcement, and it pointed applicants to public listings of existing centers to show the type of program and institutional strength expected.

Eligibility is broad across U.S.-based organizations and can include many types of government entities, higher education institutions, nonprofits, and for-profit organizations (including small businesses), as well as tribal governments and tribal organizations. The announcement explicitly highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations and U.S. territories or possessions. At the same time, the FOA draws a firm boundary around foreign involvement: non-U.S. entities are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed.

Administratively, this is a discretionary grant opportunity in the NIH health domain (CFDA 93.847), categorized under Food and Nutrition, Health. The original closing date listed for the opportunity was August 23, 2019, and the FOA was created March 21, 2019. The summary information provided does not specify an award ceiling or the expected number of awards in the extracted fields, but the intent is clear: to fund and maintain high-impact CF Research and Translation Core Centers that provide shared resources, launch new pilot projects, and knit together strong multidisciplinary CF research communities capable of driving new therapies forward.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2019-03-21.
• Applicants must submit their applications by 2019-08-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 19 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: